Articles From: ESI Announces First Quarter Fiscal 2014 Results to Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates


2013/8/6
Electro Scientific Industries, Inc. (NASDAQ:ESIO) , a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced results for its fiscal 2014 first quarter ended June 29, 2013.
Sign-up for ESI Announces First Quarter Fiscal 2014 Results investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced results for its fiscal 2014 second quarter ended September 28, 2013.
Sign-up for ESI Announces Second Quarter Fiscal 2014 Results investment picks
2014/2/4
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced results for its fiscal 2014 third quarter ended December 28, 2013.
Sign-up for ESI Announces Third Quarter Fiscal 2014 Results investment picks
2014/2/24
Electro Scientific Industries, Inc. (Nasdaq: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that Edward C.
Sign-up for ESI Appoints Edward C. Grady as CEO to Replace Nicholas Konidaris investment picks
2013/8/9
Electro Scientific Industries, Inc. (Nasdaq:ESIO) , a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that its board of directors declared a quarterly cash dividend of $0.08 per share.
Sign-up for ESI Declares Quarterly Dividend investment picks
Electro Scientific Industries, Inc. (Nasdaq: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that its board of directors declared a quarterly cash dividend of $0.08 per share.
Sign-up for ESI Declares Quarterly Dividend investment picks
2014/2/14
Electro Scientific Industries, Inc. (Nasdaq: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that its board of directors declared a quarterly cash dividend of $0.08 per share.
Sign-up for ESI Declares Quarterly Dividend investment picks
2014/2/20
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, announced that its Singapore manufacturing facility had achieved ISO 9001:2008 certification.
Sign-up for ESI Earns ISO 9001:2008 Certification investment picks
Electro Scientific Industries, Inc. (NASDAQ:ESIO) , a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today introduced its ultrafast laser scribing system, the model 9970.
Sign-up for ESI Introduces the Model 9970 for Advanced Thin Film Scribing investment picks
2014/1/31
Electro Scientific Industries, Inc. (NASDAQ:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced that it received a multi-unit order for laser systems utilizing its patented esiFIT technology.
Sign-up for ESI Receives Order from a Leading Consumer Electronics Provider investment picks
2013/10/8
Electro Scientific Industries, Inc. (Nasdaq: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, will announce results for its fiscal 2014 second quarter after the market closes on Thursday, October 31, 2013.
Sign-up for ESI Schedules Fiscal 2014 Q2 Earnings Conference Call for Thursday, October 31 investment picks
2014/1/17
Electro Scientific Industries, Inc. (Nasdaq:ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, will announce results for its fiscal 2014 third quarter after the market closes on Tuesday, February 4, 2014.
Sign-up for ESI Schedules Fiscal 2014 Q3 Earnings Conference Call for Tuesday, February 4 investment picks
2013/11/15
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor events, including: The Midtown CAP Summit is hosted by executive management from the following participating companies: Aehr Test Systems (AEHR), Axcelis (ACLS), Brooks Automation (BRKS), Camtek (CAMT), Cascade Micro (CSCD), Cohu (COHU), Electro Scientific Industries (ESIO), Entegris (ENTG), FormFactor (FORM), inTEST (INTT), Intevac (IVAC), LTX-Credence (LTXC), Mattson Technology (MTSN), Nanometrics (NANO), Nova Measuring (NVMI), Rudolph Technologies (RTEC), Tessera (TSRA), Ultra Clean Technology (UCTT), Ultratech (UTEK) and Veeco Instruments (VECO), and will feature a round-robin format consisting of a series of small group meetings.
Sign-up for ESI to Participate at Upcoming Investor Events investment picks
2014/3/4
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including: The slides from both conference presentations will be made available on ESI’s website at http://investors.esi.com .
Sign-up for ESI to Present at Two March Investor Conferences investment picks
2014/1/8
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including: The webcast and slides from both conference presentations will be made available on ESI’s website at http://investors.esi.com .
Sign-up for ESI to Present at Upcoming Investor Conferences investment picks
2013/11/15
DJ CFA SOURCE: SEC 13F-HR FILER: ESL Investments, Inc. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 The following sets forth up to 200 of the largest holdings of ESL Investments, Inc. as of Sep.
Sign-up for ESL Investments 3Q 13F: Holdings As Of Sep 30 investment picks
2013/11/15
DJ CFA SOURCE: SEC 13F-HR FILER: ESL Investments, Inc. QUARTER ENDED: 09/30/2013 SEC RECEIVED: 11/14/2013 Up to 200 of the largest sales of ESL Investments, Inc. are listed below, ordered by the number of shares sold during the three months ended Sep.
Sign-up for ESL Investments 3Q 13F: Largest Sales investment picks
2013/10/23
LAFAYETTE, La., Oct.
Sign-up for ESP Resources Completes Chemical Testing of 100+ Well Program for Major Independent Operator in South Texas investment picks
2013/8/29
LAFAYETTE, La., Aug.
Sign-up for ESP Resources Provides Update on Business and Operations investment picks
2013/10/8
Sales Productivity Increases by 50 Percent SAN MATEO, Calif.
Sign-up for eSpatial Boosts Sales Efficiency With Marketo investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that the company has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on December 23, 2013.
Sign-up for Esperion Therapeutics Added to the NASDAQ Biotechnology Index investment picks
2013/10/30
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced dosing of the first patient in a Phase 2b clinical study of ETC-1002, its lead product candidate, in patients with or without statin intolerance and hypercholesterolemia.
Sign-up for Esperion Therapeutics Announces Initiation of Phase 2b Clinical Study of ETC-1002 in Patients With or Without Statin Intolerance and Hypercholesterolemia investment picks
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today announced that full results of the Phase 2 ETC-1002-006 clinical study in patients with hypercholesterolemia and a history of statin intolerance will be presented in an oral presentation session by principal investigator Paul D.
Sign-up for Esperion Therapeutics Announces Oral Presentation on ETC-1002 at 2013 Scientific Sessions of the American Heart Association investment picks
2013/9/3
Esperion Therapeutics, Inc. (Nasdaq: ESPR) , a clinical-stage biopharmaceutical company, today announced positive top-line results from a Phase 2a study of ETC-1002 when added to statin therapy in patients with elevated levels of low density lipoprotein cholesterol (LDL-C or “bad cholesterol”). The study demonstrated that oral, once-daily ETC-1002 achieved incremental LDL-C lowering of 22 percent at eight weeks, compared with 0 percent in the placebo group, when added to 10 mg of atorvastatin (p<0.0001). ETC-1002 was well tolerated over eight weeks of treatment when added to a statin and no serious adverse events (SAEs) were reported.
Sign-up for Esperion Therapeutics Announces Positive Top-Line Results from Phase 2 Clinical Study of ETC-1002 as an Add-On to Statin Therapy in Patients with Hypercholesterolemia investment picks
2014/1/13
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M.
Sign-up for Esperion Therapeutics Announces the Appointment of Antonio M. Gotto Jr., M.D., DPhil, as Director investment picks
2014/2/13
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Mark E.
Sign-up for Esperion Therapeutics Names Mark E. McGovern, M.D., FACC, FACP, Director investment picks
2013/11/18
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance.
Sign-up for Esperion Therapeutics Presents Full Results of Phase 2 Clinical Study Demonstrating that ETC-1002 Lowered LDL-C by an Average of 32 Percent and Was Well Tolerated in Patients with Hypercholesterolemia and History of Statin Intolerance investment picks
2014/3/5
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided ETC-1002 development program updates and reported its financial results for the fourth quarter and full year ended Dec.
Sign-up for Esperion Therapeutics Provides ETC-1002 Program Update; Reports Fourth Quarter and Full Year 2013 Financial Results investment picks
2013/8/12
Esperion Therapeutics, Inc. (NASDAQ: ESPR) , a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today provided a corporate update and reported its financial results for the second quarter ended June 30, 2013.
Sign-up for Esperion Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update investment picks
2013/11/6
Esperion Therapeutics, Inc. (NASDAQ: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with hypercholesterolemia, today provided development program updates and reported its financial results for the third quarter ended September 30, 2013.
Sign-up for Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ESI Announces First Quarter Fiscal 2014 Results to Esperion Therapeutics Reports Third Quarter 2013 Financial Results and Provides Development Program Updates
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity